U.S. Markets closed

Zynex, Inc. (ZYXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.81-0.63 (-4.69%)
At close: 4:00PM EDT

12.81 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close13.44
Bid12.61 x 1400
Ask12.83 x 1400
Day's Range12.62 - 13.63
52 Week Range7.51 - 29.73
Avg. Volume846,706
Market Cap445.032M
Beta (5Y Monthly)0.61
PE Ratio (TTM)42.70
EPS (TTM)0.30
Earnings DateOct 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateDec 31, 2018
1y Target Est25.75
  • Zynex, Inc (ZYXI) Q3 2020 Earnings Call Transcript
    Motley Fool

    Zynex, Inc (ZYXI) Q3 2020 Earnings Call Transcript

    My name is Thomas Sandgaard, President and CEO of Zynex. Adjusted EBITDA for the third quarter was $2.4 million as we continue to invest in growing our sales force. The continued strength in order speaks volumes to the relationships our sales force has with many prescribers and the need for them to prescribe non-opioid, non-addictive prescription strength solutions for their patients in pain.

  • Benzinga

    Recap: Zynex Q3 Earnings

    Shares of Zynex (NASDAQ:ZYXI) decreased 2.79% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share fell 33.33% year over year to $0.04, which missed the estimate of $0.05.Revenue of $20,026,000 up by 69.47% from the same period last year, which missed the estimate of $21,130,000.Guidance Earnings guidance hasn't been issued by the company for now.The upcoming fiscal year's revenue expected to be between $80,000,000 and $81,000,000.Details Of The Call Date: Oct 27, 2020View more earnings on ZYXITime: 04:15 PMET Webcast URL: https://www.webcaster4.com/Webcast/Page/1487/38303Price Action 52-week high: $29.7352-week low: $7.51Price action over last quarter: down 25.26%Company Profile Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave, Non-Invasive Blood Volume Monitor and others.See more from Benzinga * Click here for options trades from Benzinga * 12 Healthcare Stocks Moving In Tuesday's After-Market Session * Earnings Scheduled For October 27, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.